modified for use with a steerable system. In patients with one vessel disease, coronary angioplasty was performed if a stenosis of ) 70%, was present. In multivessel disease, defined as > 70%o stenosis in two or more coronary arteries, a single percutaneous transluminal coronary angioplasty was performed to the most stenotic lesion within a major vessel. Just before angioplasty, patients received prophylactic sublingual glyceryl trinitrate (0-3 mg) and intravenous heparin (10 000 IU) to prevent possible coronary spasm and thrombosis respectively. Balloon inflations were repeated to produce a satisfactory dilatation as determined by a reduction in the pressure gradient across the lesion and an improvement in angiographic appearance of the stenosis. Multiple projection coronary arteriography was performed to confirm the result. An angioplasty procedure was considered successful when it reduced the stenotic lesion to < 50% and the transstenotic pressure gradient by > calcium channel blockers or both. All seven patients with symptoms were taking ,B blockers, nitrates, and calcium antagonists. Treadmill stress tests (table 3) were performed by 22 In patients with unstable angina there is a considerable increase in circulating platelet aggregates,2627 platelet factor IV, ,B thromboglobulin, and thromboxane A,.'2 These alterations in platelet homoeostasis strongly suggest that platelets are an important faction within the culprit lesion in the precipitation of unstable angina. Smitherman in his review of unstable angina argues that, based on such evidence, the onset of unstable angina reflects a juncture at which thrombotic events rapidly progress at the site of fixed coronary stenosis to produce dynamic coronary stenosis. Yet there are patients who despite taking maximal tolerated medications, including anticoagulants, remain refractory to medical treatment. In that subpopulation percutaneous transluminal coronary angioplasty may, by reducing the fixed coronary stenosis, prevent the development of the local environment necessary for platelet activation. Nevertheless, as angioplasty may produce iatrogenic trauma within the coronary artery heparin or some other anticoagulant should be given for a short time after angioplasty.
Long term anticoagulation was not attempted in this study. Such treatment may reduce the incidence of restenosis but no placebo controlled studies have yet been reported and published reports are uncertain whether long term anticoagulation significantly alters the prognosis after percutaneous transluminal coronary angioplasty."
In conclusion, the results of the current study indicate that one vessel percutaneous transluminal coronary angioplasty will produce the symptomatic relief of refractory unstable angina pectoris with an improvement in exercise tolerance and a low incidence of cardiac events.
